Avedro Inc., a Boston-based ophthalmic medical device and
pharmaceutical company, today announced it will present at the Cowen and
Company 34th Annual Health Care Conference in Boston on March 4th.
David Muller, Chief Executive Officer, will discuss the company in a
presentation scheduled to begin at 9:00 a.m. ET.
About Avedro, Inc.
Avedro is a privately held medical device and pharmaceutical company
advancing the science and technology of corneal cross-linking and
refractive correction. Avedro's proucts include capital equipment and
related single dose pharmaceuticals. Those products are currently used
in a procedure known as Lasik Xtra®. Over 70,000 procedures
have been successfully performed outside the US using Avedro's KXL®
System. The KXL System's accelerated cross-linking, in combination with
its pharmaceuticals, is also used to treat several important and
debilitating ophthalmic pathologies outside the United States.
Avedro distributes its products in 62 countries through 33 ophthalmic
distributors with 115 representatives. Avedro products that have
received CE Mark include: the KXL II™ System for performing PiXL™, the
KXL System for performing Lasik Xtra and Accelerated Cross-linking, and
the Avedro family of proprietary single dose pharmaceutical formulations.
Avedro's KXL System and single dose pharmaceutical products are
currently being used in three Phase III US clinical trials involving
over 100 US clinical sites. Avedro products are not for sale in the US.
[ Back To NFVZone's Homepage ]